That’s why we’re working with a range of partners, including the McLaren Technology Group and Medidata, to find new ways to use biosensors and mobile health platforms to improve patient care.
One of the first areas we’ve seen an opportunity to apply this technology is in our clinical trials. Wearable or remote biosensors and mobile health platforms provide the opportunity to get highly-detailed and accurate monitoring of a patient’s physiology and behaviour. This information can potentially improve our understanding of a disease and a patient’s response to medication.
We’ve been conducting clinical studies with biosensors and mobile devices for some time – monitoring activity and vital signs in patients, and collecting patient feedback in order to improve the quality of data we use to help our decision making in the development of new medicines. We can also use this technology to send reminders to patients to help them stay on track with a clinical trial protocol.
Using this type of technology benefits patients in other ways too – it can mean fewer trips to the clinic as biosensor devices can be used for remote monitoring. And because these devices are able to continuously monitor activity, such as the amount of time a person is active or asleep, the end result is a much more robust collection of data with minimal interruption to a patient’s day-to-day life.
Our work with biosensors and mobile health platforms is currently helping us better understand:
|Area of study||Clinical trial targets|
|Neuroscience||Amyotrophic lateral sclerosis (ALS), Stroke|
Working with our technology partners, we continue to find new and better ways to carry out clinical trials. This will help us achieve our goal of collecting the best information we can to help improve our clinical trials, reducing the burden on patients, so we can develop the best medicines for those that need them.